- Home
- NERV vs NVNI Comparison
NERV vs NVNI Comparison
Compare NERV & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NVNI
- Stock Information
- Founded
- NERV 2007
- NVNI 2019
- Country
- NERV United States
- NVNI Brazil
- Employees
- NERV N/A
- NVNI N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NVNI
- Sector
- NERV Health Care
- NVNI
- Exchange
- NERV Nasdaq
- NVNI Nasdaq
- Market Cap
- NERV 10.7M
- NVNI 10.4M
- IPO Year
- NERV 2014
- NVNI N/A
- Fundamental
- Price
- NERV $1.61
- NVNI $0.21
- Analyst Decision
- NERV Hold
- NVNI
- Analyst Count
- NERV 1
- NVNI 0
- Target Price
- NERV $5.00
- NVNI N/A
- AVG Volume (30 Days)
- NERV 15.1K
- NVNI 18.1M
- Earning Date
- NERV 04-30-2025
- NVNI 05-07-2025
- Dividend Yield
- NERV N/A
- NVNI N/A
- EPS Growth
- NERV N/A
- NVNI N/A
- EPS
- NERV 0.19
- NVNI N/A
- Revenue
- NERV N/A
- NVNI $23,558,620.00
- Revenue This Year
- NERV N/A
- NVNI $25.91
- Revenue Next Year
- NERV N/A
- NVNI $17.52
- P/E Ratio
- NERV $8.95
- NVNI N/A
- Revenue Growth
- NERV N/A
- NVNI 38.59
- 52 Week Low
- NERV $1.42
- NVNI $0.17
- 52 Week High
- NERV $3.69
- NVNI $12.19
- Technical
- Relative Strength Index (RSI)
- NERV 41.00
- NVNI 28.82
- Support Level
- NERV $1.54
- NVNI $0.20
- Resistance Level
- NERV $1.89
- NVNI $0.29
- Average True Range (ATR)
- NERV 0.11
- NVNI 0.04
- MACD
- NERV 0.00
- NVNI 0.11
- Stochastic Oscillator
- NERV 22.68
- NVNI 23.00
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.